National Cabinet met on Monday 19 April and Thursday 22 April to discuss the recalibration of the national COVID-19 Vaccination Program. The following changes have been agreed upon:
bringing forward the commencement of vaccinations for Australians 50 years and older (currently under Phase 2a) to 3 May 2021 for state, territory and Commonwealth vaccination clinics, and 17 May 2021 (or earlier where supply is available) for general practice
limiting use of AstraZeneca vaccines to people 50 years and over`
providing additional AstraZeneca doses to primary care sites
limiting the use of Pfizer vaccine to Australians under 50 years (with a few exceptions) until general availability later in the year as supply increases and this will include Aged Care workers, Disability Care Workers and residents, critical and high risk workers, healthcare workers, and people with underlying medical condition
a progressive geographical expansion of state/territory Pfizer clinics to ensure distribution to those eligible Phase 1a and 1b under 50s; and
expanding the number of Commonwealth and state and territory-operated Pfizer vaccination sites as supplies increase.
National Cabinet reinforced that general practice (including Commonwealth Vaccination Clinics and Aboriginal and Torres Strait Islander Community Controlled Health Services) will continue to be the primary model of delivery for people 50 years and older.
Click here for daily updates on the COVID-19 vaccine roll-out.
Testing for immunity after vaccination
Testing for serological markers of immunity (anti-spike antibodies or neutralising antibodies) to COVID-19 is not recommended. An immune correlate of protection has not yet been established for SARS-CoV-2 infection and therefore serology is not useful in determining whether a vaccinated person is protected against COVID-19.
Billing of MBS COVID-19 vaccination numbers by non-participating practices
All MBS COVID-19 vaccine numbers, including the Suitability Assessment Service numbers, can only be accessed by those practices participating in the Government’s COVID-19 vaccination roll-out.
General practices that are not participating in the vaccination delivery program cannot bill to MBS COVID-19 vaccination numbers. This includes consultations that involve discussing a COVID-19 vaccine.
The Australian Technical Advisory Group on Immunisation has developed advice on the risk-benefit of receiving an AstraZeneca vaccination to assist vaccination providers in supporting patients to make an informed decision.
Below are the latest clinical updates from the Department of Health:
If the process of administering a COVID-19 vaccine is interrupted and the majority of the dose has not been given, repeat the whole dose as soon as possible. If most has been given, repeat dosing is not required. If there is uncertainty around this, it is acceptable to repeat the whole dose.
If an individual contracts COVID-19 between the first and second dose of the vaccine, the second dose of Pfizer should be given a minimum of eight weeks after recovery and the second dose of AstraZeneca should be given a minimum of 12 weeks after recovery. These time periods may be shortened if an individual is very likely to be in contact with cases of COVID-19. In these instances, clinicians may wish to seek advise from a specialist immunisation service.
Click here for further clinical updates and considerations.
Upcoming webinar
Medcast and CESPHN are holding a webinar on Responding to vaccine hesitancy on the front line on 12 May at 7.00 pm.
The webinar will cover the following:
a clinical update on vaccines and latest safety issues from Prof Kristine McCartney (NCIRS)
A GP perspective on the opportunities and challenges with Dr Duncan McKinnon (GP Bega Valley Medical Centre)
Communicating with people about the vaccine with Prof Julie Leask (The University of Sydney)
If you want to check locations visited by COVID-19 cases near you the following website offers a helpful interactive map: https://covid19nearme.com.au/state/nsw
Maroubra Medicare Urgent Care Clinic (UCC) is now open The Maroubra Medicare Urgent Care Clinic (UCC) is now open, seven days a week, from 8.00am to 8.00pm. It was officially launched by member for Kingsford Smith, the hon Matt Thistlethwaite MP (pictured at the launch with CESPHN CEO Nathalie Hansen…
Media Release: Central and Eastern Sydney PHN releases Healthy Ageing Strategy to empower older people In response to the increasing longevity and rapid growth of the older population the Central and Eastern Sydney Primary Health Network (CESPHN) is proud to release its new Healthy Ageing Strategy 2023-2028. This comprehensive strategy…
Immunisation Weekly Update: Are your vaccines ready for summer? In the summer season, storms are more likely to occur, which can lead to power outages. Refer to the Cold Chain Toolkit to ensure all vaccination storage requirements are in place should an outage occur. Disposal of Zostavax® Zostavax® vaccine will…
Immunisation Weekly Update: COVID-19 XBB.1.5 vaccine onboarding The Australian Government has accepted the latest advice from ATAGI on the use of the new COVID-19 XBB 1.5 vaccine as part of the National COVID-19 Vaccine Program. All sites currently participating in the COVID-19 Vaccination Program will be onboarded for the three…
Immunisation Weekly Update: Increase in COVID-19 infection cases ATAGI notes a recent increase in COVID-19 cases since November 2023 across Australia and encourages all eligible people who have not yet had their recommended 2023 COVID-19 vaccine dose/s to receive them as soon as possible. A first 2023 dose is recommended…
Immunisation Weekly Update: Vaccination coverage in RACF Australian Immunisation Register (AIR) data suggests that only 36% of people aged 70+ living in the central and eastern Sydney PHN region are immunised against Pneumococcal diseases. Immunisation providers are reminded to check AIR immunisation history statements of patients going into Residential Aged…
Immunisation Weekly Update: Introduction of Shingrix® to the NIP From 1 November 2023, the shingles vaccine Shingrix® will replace Zostavax® on the National Immunisation Program (NIP) schedule for the prevention of shingles and post-herpetic neuralgia. It will be available for eligible people most at risk of complications from shingles. A…
NSW urged to prepare for heat wave Severe heatwave conditions are forecast in NSW in the coming days. Please read the NSW Health media release about taking steps to prevent heat-related illness. For further information about staying safe in a heatwave, visit Beat the heat and stay well during hot…